nodes	percent_of_prediction	percent_of_DWPC	metapath
Dicyclomine—Tachyarrhythmia—Epirubicin—thyroid cancer	0.0354	0.0354	CcSEcCtD
Dicyclomine—Tachyarrhythmia—Doxorubicin—thyroid cancer	0.0328	0.0328	CcSEcCtD
Dicyclomine—Lethargy—Vandetanib—thyroid cancer	0.0192	0.0192	CcSEcCtD
Dicyclomine—Drug hypersensitivity—Epirubicin—thyroid cancer	0.0161	0.0161	CcSEcCtD
Dicyclomine—Drug hypersensitivity—Doxorubicin—thyroid cancer	0.0149	0.0149	CcSEcCtD
Dicyclomine—Eye disorder—Vandetanib—thyroid cancer	0.0122	0.0122	CcSEcCtD
Dicyclomine—Cardiac disorder—Vandetanib—thyroid cancer	0.0121	0.0121	CcSEcCtD
Dicyclomine—Mood swings—Sorafenib—thyroid cancer	0.012	0.012	CcSEcCtD
Dicyclomine—Mediastinal disorder—Vandetanib—thyroid cancer	0.0117	0.0117	CcSEcCtD
Dicyclomine—Breast disorder—Sorafenib—thyroid cancer	0.0115	0.0115	CcSEcCtD
Dicyclomine—Mental disorder—Vandetanib—thyroid cancer	0.0114	0.0114	CcSEcCtD
Dicyclomine—Vision blurred—Vandetanib—thyroid cancer	0.0107	0.0107	CcSEcCtD
Dicyclomine—Erectile dysfunction—Sorafenib—thyroid cancer	0.0101	0.0101	CcSEcCtD
Dicyclomine—Loss of consciousness—Vandetanib—thyroid cancer	0.00997	0.00997	CcSEcCtD
Dicyclomine—Hypertension—Vandetanib—thyroid cancer	0.00979	0.00979	CcSEcCtD
Dicyclomine—Dry mouth—Vandetanib—thyroid cancer	0.00944	0.00944	CcSEcCtD
Dicyclomine—Paralysis—Epirubicin—thyroid cancer	0.00931	0.00931	CcSEcCtD
Dicyclomine—Oedema—Vandetanib—thyroid cancer	0.00926	0.00926	CcSEcCtD
Dicyclomine—Thrombosis—Epirubicin—thyroid cancer	0.00914	0.00914	CcSEcCtD
Dicyclomine—Nervous system disorder—Vandetanib—thyroid cancer	0.00908	0.00908	CcSEcCtD
Dicyclomine—Dermatitis atopic—Epirubicin—thyroid cancer	0.00874	0.00874	CcSEcCtD
Dicyclomine—Paralysis—Doxorubicin—thyroid cancer	0.00861	0.00861	CcSEcCtD
Dicyclomine—Thrombosis—Doxorubicin—thyroid cancer	0.00846	0.00846	CcSEcCtD
Dicyclomine—Insomnia—Vandetanib—thyroid cancer	0.00837	0.00837	CcSEcCtD
Dicyclomine—Paraesthesia—Vandetanib—thyroid cancer	0.00831	0.00831	CcSEcCtD
Dicyclomine—Dyspnoea—Vandetanib—thyroid cancer	0.00825	0.00825	CcSEcCtD
Dicyclomine—Necrosis—Epirubicin—thyroid cancer	0.00824	0.00824	CcSEcCtD
Dicyclomine—Cardiac disorder—Sorafenib—thyroid cancer	0.00816	0.00816	CcSEcCtD
Dicyclomine—Dyspepsia—Vandetanib—thyroid cancer	0.00815	0.00815	CcSEcCtD
Dicyclomine—Dermatitis atopic—Doxorubicin—thyroid cancer	0.00809	0.00809	CcSEcCtD
Dicyclomine—Decreased appetite—Vandetanib—thyroid cancer	0.00805	0.00805	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00799	0.00799	CcSEcCtD
Dicyclomine—Ageusia—Epirubicin—thyroid cancer	0.00798	0.00798	CcSEcCtD
Dicyclomine—Fatigue—Vandetanib—thyroid cancer	0.00798	0.00798	CcSEcCtD
Dicyclomine—Immune system disorder—Sorafenib—thyroid cancer	0.00794	0.00794	CcSEcCtD
Dicyclomine—Mediastinal disorder—Sorafenib—thyroid cancer	0.00792	0.00792	CcSEcCtD
Dicyclomine—Pain—Vandetanib—thyroid cancer	0.00792	0.00792	CcSEcCtD
Dicyclomine—Constipation—Vandetanib—thyroid cancer	0.00792	0.00792	CcSEcCtD
Dicyclomine—Mental disorder—Sorafenib—thyroid cancer	0.0077	0.0077	CcSEcCtD
Dicyclomine—Erythema—Sorafenib—thyroid cancer	0.00765	0.00765	CcSEcCtD
Dicyclomine—Necrosis—Doxorubicin—thyroid cancer	0.00762	0.00762	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00757	0.00757	CcSEcCtD
Dicyclomine—Delirium—Epirubicin—thyroid cancer	0.00752	0.00752	CcSEcCtD
Dicyclomine—Ageusia—Doxorubicin—thyroid cancer	0.00739	0.00739	CcSEcCtD
Dicyclomine—Abdominal pain—Vandetanib—thyroid cancer	0.00732	0.00732	CcSEcCtD
Dicyclomine—Angioedema—Sorafenib—thyroid cancer	0.00699	0.00699	CcSEcCtD
Dicyclomine—Delirium—Doxorubicin—thyroid cancer	0.00696	0.00696	CcSEcCtD
Dicyclomine—Dyskinesia—Epirubicin—thyroid cancer	0.00688	0.00688	CcSEcCtD
Dicyclomine—Syncope—Sorafenib—thyroid cancer	0.00686	0.00686	CcSEcCtD
Dicyclomine—Loss of consciousness—Sorafenib—thyroid cancer	0.00672	0.00672	CcSEcCtD
Dicyclomine—Asthenia—Vandetanib—thyroid cancer	0.00664	0.00664	CcSEcCtD
Dicyclomine—Hypertension—Sorafenib—thyroid cancer	0.00661	0.00661	CcSEcCtD
Dicyclomine—Pruritus—Vandetanib—thyroid cancer	0.00655	0.00655	CcSEcCtD
Dicyclomine—Injection site reaction—Epirubicin—thyroid cancer	0.00643	0.00643	CcSEcCtD
Dicyclomine—Dry mouth—Sorafenib—thyroid cancer	0.00637	0.00637	CcSEcCtD
Dicyclomine—Dyskinesia—Doxorubicin—thyroid cancer	0.00637	0.00637	CcSEcCtD
Dicyclomine—Anaphylactic shock—Sorafenib—thyroid cancer	0.00624	0.00624	CcSEcCtD
Dicyclomine—Shock—Sorafenib—thyroid cancer	0.00614	0.00614	CcSEcCtD
Dicyclomine—Nervous system disorder—Sorafenib—thyroid cancer	0.00612	0.00612	CcSEcCtD
Dicyclomine—Dizziness—Vandetanib—thyroid cancer	0.00612	0.00612	CcSEcCtD
Dicyclomine—Anorexia—Sorafenib—thyroid cancer	0.00595	0.00595	CcSEcCtD
Dicyclomine—Injection site reaction—Doxorubicin—thyroid cancer	0.00595	0.00595	CcSEcCtD
Dicyclomine—Vomiting—Vandetanib—thyroid cancer	0.00589	0.00589	CcSEcCtD
Dicyclomine—Rash—Vandetanib—thyroid cancer	0.00584	0.00584	CcSEcCtD
Dicyclomine—Dermatitis—Vandetanib—thyroid cancer	0.00583	0.00583	CcSEcCtD
Dicyclomine—Headache—Vandetanib—thyroid cancer	0.0058	0.0058	CcSEcCtD
Dicyclomine—Dyspnoea—Sorafenib—thyroid cancer	0.00557	0.00557	CcSEcCtD
Dicyclomine—Nausea—Vandetanib—thyroid cancer	0.0055	0.0055	CcSEcCtD
Dicyclomine—Dyspepsia—Sorafenib—thyroid cancer	0.0055	0.0055	CcSEcCtD
Dicyclomine—Decreased appetite—Sorafenib—thyroid cancer	0.00543	0.00543	CcSEcCtD
Dicyclomine—Thrombophlebitis—Epirubicin—thyroid cancer	0.00542	0.00542	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00539	0.00539	CcSEcCtD
Dicyclomine—Fatigue—Sorafenib—thyroid cancer	0.00538	0.00538	CcSEcCtD
Dicyclomine—Pain—Sorafenib—thyroid cancer	0.00534	0.00534	CcSEcCtD
Dicyclomine—Constipation—Sorafenib—thyroid cancer	0.00534	0.00534	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00511	0.00511	CcSEcCtD
Dicyclomine—Thrombophlebitis—Doxorubicin—thyroid cancer	0.00502	0.00502	CcSEcCtD
Dicyclomine—Urticaria—Sorafenib—thyroid cancer	0.00496	0.00496	CcSEcCtD
Dicyclomine—Abdominal pain—Sorafenib—thyroid cancer	0.00494	0.00494	CcSEcCtD
Dicyclomine—Lethargy—Epirubicin—thyroid cancer	0.00479	0.00479	CcSEcCtD
Dicyclomine—Diplopia—Epirubicin—thyroid cancer	0.0047	0.0047	CcSEcCtD
Dicyclomine—Affect lability—Epirubicin—thyroid cancer	0.00462	0.00462	CcSEcCtD
Dicyclomine—Hypersensitivity—Sorafenib—thyroid cancer	0.0046	0.0046	CcSEcCtD
Dicyclomine—Face oedema—Epirubicin—thyroid cancer	0.00453	0.00453	CcSEcCtD
Dicyclomine—Asthenia—Sorafenib—thyroid cancer	0.00448	0.00448	CcSEcCtD
Dicyclomine—Mood swings—Epirubicin—thyroid cancer	0.00445	0.00445	CcSEcCtD
Dicyclomine—Lethargy—Doxorubicin—thyroid cancer	0.00443	0.00443	CcSEcCtD
Dicyclomine—Pruritus—Sorafenib—thyroid cancer	0.00442	0.00442	CcSEcCtD
Dicyclomine—Diplopia—Doxorubicin—thyroid cancer	0.00434	0.00434	CcSEcCtD
Dicyclomine—Affect lability—Doxorubicin—thyroid cancer	0.00428	0.00428	CcSEcCtD
Dicyclomine—Breast disorder—Epirubicin—thyroid cancer	0.00424	0.00424	CcSEcCtD
Dicyclomine—Face oedema—Doxorubicin—thyroid cancer	0.00419	0.00419	CcSEcCtD
Dicyclomine—Muscular weakness—Epirubicin—thyroid cancer	0.00414	0.00414	CcSEcCtD
Dicyclomine—Dizziness—Sorafenib—thyroid cancer	0.00413	0.00413	CcSEcCtD
Dicyclomine—Mood swings—Doxorubicin—thyroid cancer	0.00412	0.00412	CcSEcCtD
Dicyclomine—Abdominal distension—Epirubicin—thyroid cancer	0.00409	0.00409	CcSEcCtD
Dicyclomine—Vomiting—Sorafenib—thyroid cancer	0.00397	0.00397	CcSEcCtD
Dicyclomine—Rash—Sorafenib—thyroid cancer	0.00394	0.00394	CcSEcCtD
Dicyclomine—Dermatitis—Sorafenib—thyroid cancer	0.00393	0.00393	CcSEcCtD
Dicyclomine—Breast disorder—Doxorubicin—thyroid cancer	0.00393	0.00393	CcSEcCtD
Dicyclomine—Headache—Sorafenib—thyroid cancer	0.00391	0.00391	CcSEcCtD
Dicyclomine—Muscular weakness—Doxorubicin—thyroid cancer	0.00383	0.00383	CcSEcCtD
Dicyclomine—Abdominal distension—Doxorubicin—thyroid cancer	0.00378	0.00378	CcSEcCtD
Dicyclomine—Nausea—Sorafenib—thyroid cancer	0.00371	0.00371	CcSEcCtD
Dicyclomine—Drowsiness—Epirubicin—thyroid cancer	0.00362	0.00362	CcSEcCtD
Dicyclomine—Drowsiness—Doxorubicin—thyroid cancer	0.00335	0.00335	CcSEcCtD
Dicyclomine—Hypoaesthesia—Epirubicin—thyroid cancer	0.00323	0.00323	CcSEcCtD
Dicyclomine—Eye disorder—Epirubicin—thyroid cancer	0.00304	0.00304	CcSEcCtD
Dicyclomine—Cardiac disorder—Epirubicin—thyroid cancer	0.00301	0.00301	CcSEcCtD
Dicyclomine—Hypoaesthesia—Doxorubicin—thyroid cancer	0.00299	0.00299	CcSEcCtD
Dicyclomine—Immune system disorder—Epirubicin—thyroid cancer	0.00293	0.00293	CcSEcCtD
Dicyclomine—Mediastinal disorder—Epirubicin—thyroid cancer	0.00293	0.00293	CcSEcCtD
Dicyclomine—Mental disorder—Epirubicin—thyroid cancer	0.00285	0.00285	CcSEcCtD
Dicyclomine—Erythema—Epirubicin—thyroid cancer	0.00283	0.00283	CcSEcCtD
Dicyclomine—Eye disorder—Doxorubicin—thyroid cancer	0.00281	0.00281	CcSEcCtD
Dicyclomine—Cardiac disorder—Doxorubicin—thyroid cancer	0.00279	0.00279	CcSEcCtD
Dicyclomine—Tension—Epirubicin—thyroid cancer	0.00277	0.00277	CcSEcCtD
Dicyclomine—Nervousness—Epirubicin—thyroid cancer	0.00275	0.00275	CcSEcCtD
Dicyclomine—Immune system disorder—Doxorubicin—thyroid cancer	0.00271	0.00271	CcSEcCtD
Dicyclomine—Mediastinal disorder—Doxorubicin—thyroid cancer	0.00271	0.00271	CcSEcCtD
Dicyclomine—Vision blurred—Epirubicin—thyroid cancer	0.00266	0.00266	CcSEcCtD
Dicyclomine—Mental disorder—Doxorubicin—thyroid cancer	0.00263	0.00263	CcSEcCtD
Dicyclomine—Ill-defined disorder—Epirubicin—thyroid cancer	0.00262	0.00262	CcSEcCtD
Dicyclomine—Erythema—Doxorubicin—thyroid cancer	0.00262	0.00262	CcSEcCtD
Dicyclomine—Agitation—Epirubicin—thyroid cancer	0.0026	0.0026	CcSEcCtD
Dicyclomine—Tension—Doxorubicin—thyroid cancer	0.00257	0.00257	CcSEcCtD
Dicyclomine—Malaise—Epirubicin—thyroid cancer	0.00255	0.00255	CcSEcCtD
Dicyclomine—Nervousness—Doxorubicin—thyroid cancer	0.00254	0.00254	CcSEcCtD
Dicyclomine—Syncope—Epirubicin—thyroid cancer	0.00254	0.00254	CcSEcCtD
Dicyclomine—Palpitations—Epirubicin—thyroid cancer	0.0025	0.0025	CcSEcCtD
Dicyclomine—Loss of consciousness—Epirubicin—thyroid cancer	0.00249	0.00249	CcSEcCtD
Dicyclomine—Vision blurred—Doxorubicin—thyroid cancer	0.00247	0.00247	CcSEcCtD
Dicyclomine—Hypertension—Epirubicin—thyroid cancer	0.00244	0.00244	CcSEcCtD
Dicyclomine—Ill-defined disorder—Doxorubicin—thyroid cancer	0.00243	0.00243	CcSEcCtD
Dicyclomine—Agitation—Doxorubicin—thyroid cancer	0.0024	0.0024	CcSEcCtD
Dicyclomine—Discomfort—Epirubicin—thyroid cancer	0.00238	0.00238	CcSEcCtD
Dicyclomine—Malaise—Doxorubicin—thyroid cancer	0.00236	0.00236	CcSEcCtD
Dicyclomine—Dry mouth—Epirubicin—thyroid cancer	0.00235	0.00235	CcSEcCtD
Dicyclomine—Syncope—Doxorubicin—thyroid cancer	0.00235	0.00235	CcSEcCtD
Dicyclomine—Confusional state—Epirubicin—thyroid cancer	0.00233	0.00233	CcSEcCtD
Dicyclomine—Palpitations—Doxorubicin—thyroid cancer	0.00231	0.00231	CcSEcCtD
Dicyclomine—Anaphylactic shock—Epirubicin—thyroid cancer	0.00231	0.00231	CcSEcCtD
Dicyclomine—Oedema—Epirubicin—thyroid cancer	0.00231	0.00231	CcSEcCtD
Dicyclomine—Loss of consciousness—Doxorubicin—thyroid cancer	0.0023	0.0023	CcSEcCtD
Dicyclomine—Shock—Epirubicin—thyroid cancer	0.00227	0.00227	CcSEcCtD
Dicyclomine—Nervous system disorder—Epirubicin—thyroid cancer	0.00226	0.00226	CcSEcCtD
Dicyclomine—Hypertension—Doxorubicin—thyroid cancer	0.00226	0.00226	CcSEcCtD
Dicyclomine—Tachycardia—Epirubicin—thyroid cancer	0.00225	0.00225	CcSEcCtD
Dicyclomine—Discomfort—Doxorubicin—thyroid cancer	0.0022	0.0022	CcSEcCtD
Dicyclomine—Anorexia—Epirubicin—thyroid cancer	0.0022	0.0022	CcSEcCtD
Dicyclomine—Dry mouth—Doxorubicin—thyroid cancer	0.00218	0.00218	CcSEcCtD
Dicyclomine—Confusional state—Doxorubicin—thyroid cancer	0.00215	0.00215	CcSEcCtD
Dicyclomine—Oedema—Doxorubicin—thyroid cancer	0.00214	0.00214	CcSEcCtD
Dicyclomine—Anaphylactic shock—Doxorubicin—thyroid cancer	0.00214	0.00214	CcSEcCtD
Dicyclomine—Shock—Doxorubicin—thyroid cancer	0.0021	0.0021	CcSEcCtD
Dicyclomine—Nervous system disorder—Doxorubicin—thyroid cancer	0.00209	0.00209	CcSEcCtD
Dicyclomine—Insomnia—Epirubicin—thyroid cancer	0.00209	0.00209	CcSEcCtD
Dicyclomine—Tachycardia—Doxorubicin—thyroid cancer	0.00208	0.00208	CcSEcCtD
Dicyclomine—Paraesthesia—Epirubicin—thyroid cancer	0.00207	0.00207	CcSEcCtD
Dicyclomine—Dyspnoea—Epirubicin—thyroid cancer	0.00206	0.00206	CcSEcCtD
Dicyclomine—Somnolence—Epirubicin—thyroid cancer	0.00205	0.00205	CcSEcCtD
Dicyclomine—Anorexia—Doxorubicin—thyroid cancer	0.00204	0.00204	CcSEcCtD
Dicyclomine—Dyspepsia—Epirubicin—thyroid cancer	0.00203	0.00203	CcSEcCtD
Dicyclomine—Decreased appetite—Epirubicin—thyroid cancer	0.00201	0.00201	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.00199	0.00199	CcSEcCtD
Dicyclomine—Fatigue—Epirubicin—thyroid cancer	0.00199	0.00199	CcSEcCtD
Dicyclomine—Pain—Epirubicin—thyroid cancer	0.00197	0.00197	CcSEcCtD
Dicyclomine—Constipation—Epirubicin—thyroid cancer	0.00197	0.00197	CcSEcCtD
Dicyclomine—Insomnia—Doxorubicin—thyroid cancer	0.00193	0.00193	CcSEcCtD
Dicyclomine—Paraesthesia—Doxorubicin—thyroid cancer	0.00192	0.00192	CcSEcCtD
Dicyclomine—Dyspnoea—Doxorubicin—thyroid cancer	0.0019	0.0019	CcSEcCtD
Dicyclomine—Feeling abnormal—Epirubicin—thyroid cancer	0.0019	0.0019	CcSEcCtD
Dicyclomine—Somnolence—Doxorubicin—thyroid cancer	0.0019	0.0019	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Epirubicin—thyroid cancer	0.00189	0.00189	CcSEcCtD
Dicyclomine—Dyspepsia—Doxorubicin—thyroid cancer	0.00188	0.00188	CcSEcCtD
Dicyclomine—Decreased appetite—Doxorubicin—thyroid cancer	0.00186	0.00186	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.00184	0.00184	CcSEcCtD
Dicyclomine—Fatigue—Doxorubicin—thyroid cancer	0.00184	0.00184	CcSEcCtD
Dicyclomine—Urticaria—Epirubicin—thyroid cancer	0.00183	0.00183	CcSEcCtD
Dicyclomine—Pain—Doxorubicin—thyroid cancer	0.00183	0.00183	CcSEcCtD
Dicyclomine—Constipation—Doxorubicin—thyroid cancer	0.00183	0.00183	CcSEcCtD
Dicyclomine—Abdominal pain—Epirubicin—thyroid cancer	0.00182	0.00182	CcSEcCtD
Dicyclomine—Feeling abnormal—Doxorubicin—thyroid cancer	0.00176	0.00176	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.00175	0.00175	CcSEcCtD
Dicyclomine—Hypersensitivity—Epirubicin—thyroid cancer	0.0017	0.0017	CcSEcCtD
Dicyclomine—Urticaria—Doxorubicin—thyroid cancer	0.0017	0.0017	CcSEcCtD
Dicyclomine—Abdominal pain—Doxorubicin—thyroid cancer	0.00169	0.00169	CcSEcCtD
Dicyclomine—Asthenia—Epirubicin—thyroid cancer	0.00166	0.00166	CcSEcCtD
Dicyclomine—Pruritus—Epirubicin—thyroid cancer	0.00163	0.00163	CcSEcCtD
Dicyclomine—Hypersensitivity—Doxorubicin—thyroid cancer	0.00157	0.00157	CcSEcCtD
Dicyclomine—Asthenia—Doxorubicin—thyroid cancer	0.00153	0.00153	CcSEcCtD
Dicyclomine—Dizziness—Epirubicin—thyroid cancer	0.00153	0.00153	CcSEcCtD
Dicyclomine—Pruritus—Doxorubicin—thyroid cancer	0.00151	0.00151	CcSEcCtD
Dicyclomine—Vomiting—Epirubicin—thyroid cancer	0.00147	0.00147	CcSEcCtD
Dicyclomine—Rash—Epirubicin—thyroid cancer	0.00145	0.00145	CcSEcCtD
Dicyclomine—Dermatitis—Epirubicin—thyroid cancer	0.00145	0.00145	CcSEcCtD
Dicyclomine—Headache—Epirubicin—thyroid cancer	0.00145	0.00145	CcSEcCtD
Dicyclomine—Dizziness—Doxorubicin—thyroid cancer	0.00141	0.00141	CcSEcCtD
Dicyclomine—Nausea—Epirubicin—thyroid cancer	0.00137	0.00137	CcSEcCtD
Dicyclomine—Vomiting—Doxorubicin—thyroid cancer	0.00136	0.00136	CcSEcCtD
Dicyclomine—Rash—Doxorubicin—thyroid cancer	0.00135	0.00135	CcSEcCtD
Dicyclomine—Dermatitis—Doxorubicin—thyroid cancer	0.00135	0.00135	CcSEcCtD
Dicyclomine—Headache—Doxorubicin—thyroid cancer	0.00134	0.00134	CcSEcCtD
Dicyclomine—Nausea—Doxorubicin—thyroid cancer	0.00127	0.00127	CcSEcCtD
